Sign in

    Vivian Cervantes

    Managing Director at BTIG

    Vivian Cervantes is a Managing Director at Gilmartin Group, specializing in investor relations within the healthcare and life sciences sectors. She has covered companies such as Bionano Genomics Inc and Alpha Teknova Inc, and has engaged in high-level investor strategies, though specific industry performance metrics and public rankings are not disclosed. Prior to her current senior role at Gilmartin Group, she built her expertise at BTIG, contributing to research and investor engagement, with a career spanning public company advisement and transaction communication. Cervantes holds advanced knowledge in capital markets and investor communications strategies, and is recognized for moderating industry panels, but verifiable securities licensing or FINRA registrations are not publicly listed.

    Vivian Cervantes's questions to Bionano Genomics (BNGO) leadership

    Vivian Cervantes's questions to Bionano Genomics (BNGO) leadership • Q2 2025

    Question

    Vivian Cervantes, on for Mark Massaro, questioned if the instrument placement guidance for the second half of the year was conservative, asked about the drivers for the strong flow cell sales and the typical ramp-up time for new customers, and inquired about the company's perspective on strategic partnerships or M&A.

    Answer

    CEO Eric Holmlin acknowledged the raised guidance could be seen as conservative but deemed it appropriate given potential installation timelines. He attributed the 17% growth in flow cell sales to strong execution and focused support for routine users, estimating a 6-to-9-month timeframe for a new lab to reach routine use. On M&A, Dr. Holmlin stated that Bionano is likely on the radar of strategics due to its advanced commercial stage and improved financials, but the company remains highly committed to executing its own digital pathology strategy.

    Ask Fintool Equity Research AI

    Vivian Cervantes's questions to Alpha Teknova (TKNO) leadership

    Vivian Cervantes's questions to Alpha Teknova (TKNO) leadership • Q1 2025

    Question

    Vivian Cervantes inquired about the demand from cell and gene therapy customers following the recent FDA leadership change, any month-over-month improvements in the biotech funding landscape, and the dynamics of revenue per customer as new clients are onboarded.

    Answer

    President and CEO Stephen Gunstream stated it was too early to see an impact from the FDA leadership change but noted that the market remains challenging for early-stage biotechs. However, he affirmed that Teknova's key customers are executing their plans, supporting the company's 15% growth guidance for the custom biopharma segment. Gunstream also explained that while new, smaller customers can initially lower the average revenue per customer, the company still expects a 30-fold increase in spend as therapies progress from Phase I to commercialization.

    Ask Fintool Equity Research AI